Skip to main content
. 2022 May 13;14(2):435–464. doi: 10.1016/j.jcmgh.2022.05.003

Figure 8.

Figure 8

The Fzd5,8-specific mimetic, SZN-1326-p, showed dose response efficacy in the acute DSS model. (A–J) H&E stain of cross sections of transverse colon of animals treated with (A) no DSS, (B) DSS + anti-GFP, (C) DSS + 1 dose of 1mpk SZN-1326-p, (D) DSS + 1 doses of 3 mpk SZN-1326-p, (E) DSS + 1 dose of 10 mpk SZN-1326-p, (F) DSS + 1 dose of 30 mpk SZN-1326-p, (G) DSS + 2 doses of 0.3 mpk SZN-1326-p, (H) DSS + 2 doses of 1mpk SZN-1326-p, (I) DSS + 2 doses of 3 mpk SZN-1326-p, and (J) DSS + 2 doses of 10 mpk SZN-1326-p. (K–N) Histology score reading of the 5 indicated parameters by an independent pathologist, on colon samples harvested at termination on day 10. (P–R) Serum levels of proinflammatory cytokines TNF-α, IL-6, and IL-8 measured in the SZN-1326-p dose response study. (S-U) Colon tissue cytokine levels of TNF-α, IL-6, and IL-8 measured in the SZN-1326-p dose response study.